SG11201605588YA - Compositions and methods for treatment of abnormal cell growth - Google Patents

Compositions and methods for treatment of abnormal cell growth

Info

Publication number
SG11201605588YA
SG11201605588YA SG11201605588YA SG11201605588YA SG11201605588YA SG 11201605588Y A SG11201605588Y A SG 11201605588YA SG 11201605588Y A SG11201605588Y A SG 11201605588YA SG 11201605588Y A SG11201605588Y A SG 11201605588YA SG 11201605588Y A SG11201605588Y A SG 11201605588YA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
methods
cell growth
abnormal cell
Prior art date
Application number
SG11201605588YA
Other languages
English (en)
Inventor
Mahesh Padval
Paul Okwabi Nkansah
Original Assignee
Verastem Inc
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc, Pfizer filed Critical Verastem Inc
Publication of SG11201605588YA publication Critical patent/SG11201605588YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
SG11201605588YA 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth SG11201605588YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09
PCT/US2015/010810 WO2015106096A1 (fr) 2014-01-09 2015-01-09 Compositions et méthodes pour le traitement d'une croissance cellulaire anormale

Publications (1)

Publication Number Publication Date
SG11201605588YA true SG11201605588YA (en) 2016-08-30

Family

ID=52434976

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201605588YA SG11201605588YA (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth
SG10201805890QA SG10201805890QA (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201805890QA SG10201805890QA (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Country Status (15)

Country Link
US (3) US20150190346A1 (fr)
EP (2) EP3900726A1 (fr)
JP (4) JP6647204B2 (fr)
KR (2) KR102444494B1 (fr)
CN (2) CN115708827A (fr)
AU (3) AU2015204597B2 (fr)
BR (1) BR112016016021B1 (fr)
CA (1) CA2936283C (fr)
DK (1) DK3091981T3 (fr)
ES (1) ES2870562T3 (fr)
IL (2) IL246667B (fr)
MX (2) MX2016009056A (fr)
NZ (2) NZ721934A (fr)
SG (2) SG11201605588YA (fr)
WO (1) WO2015106096A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7550393B2 (ja) * 2018-05-15 2024-09-13 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド 低分子ｅｇｆｒ阻害剤を含む医薬組成物及びその製造方法
WO2021047783A1 (fr) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 en combinaison avec ch5126766 pour le traitement du cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024037498A1 (fr) * 2022-08-15 2024-02-22 海创药业股份有限公司 Polythérapie pour le traitement du cancer de l'ovaire

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
JP2007501217A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク コレステリルエステル転送タンパク質阻害剤を制御放出し、そしてＨＭＧ−ＣｏＡレダクターゼ阻害剤を即時放出する投薬形態
WO2006061712A2 (fr) * 2004-12-10 2006-06-15 Pfizer Inc. Utilisation d'inhibiteurs de mek dans le traitement d'une croissance cellulaire anormale
AP2009005010A0 (en) * 2007-04-18 2009-10-31 Pfizer Prod Inc Sulfonyl amide derivatives for the treatment of abnormal cell growth
CA2733908C (fr) * 2008-08-13 2017-05-30 Vertex Pharmaceuticals Incorporated Composition pharmaceutique renfermant une dispersion solide de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoqsinolin e-3-carboxamide
WO2011112922A2 (fr) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-cristaux et formulations pharmaceutiques comprenant ceux-ci
CA2808501A1 (fr) * 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Composition pharmaceutique a base de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yle)cyclopropanecarboxamide et son administration
BR112013022788A2 (pt) * 2011-03-08 2016-12-06 Zalicus Pharmaceuticals Ltd "composição farmacêutica compreendendo uma dispersão sólida de 1-(4-benzidrilpiperazin-1-il)-3,3-difenilpropan-1-ona"
EP2572731A1 (fr) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations à base de dispersions solides

Also Published As

Publication number Publication date
MX2016009056A (es) 2017-01-23
DK3091981T3 (da) 2021-05-31
CA2936283A1 (fr) 2015-07-16
WO2015106096A1 (fr) 2015-07-16
IL292054A (en) 2022-06-01
BR112016016021B1 (pt) 2023-01-10
JP2023065568A (ja) 2023-05-12
AU2020210153B2 (en) 2022-07-21
MX2021008225A (es) 2021-08-11
AU2015204597A1 (en) 2016-07-21
CA2936283C (fr) 2023-02-28
BR112016016021A8 (pt) 2018-04-17
NZ760233A (en) 2022-04-29
IL246667A0 (en) 2016-08-31
IL246667B (en) 2022-05-01
SG10201805890QA (en) 2018-08-30
EP3091981B1 (fr) 2021-03-10
AU2022256144A1 (en) 2022-11-24
EP3900726A1 (fr) 2021-10-27
US20150190346A1 (en) 2015-07-09
BR112016016021A2 (pt) 2017-09-19
JP2017502062A (ja) 2017-01-19
JP6647204B2 (ja) 2020-02-14
ES2870562T3 (es) 2021-10-27
EP3091981A1 (fr) 2016-11-16
AU2020210153A1 (en) 2020-08-13
JP2022001587A (ja) 2022-01-06
CN106102744A (zh) 2016-11-09
AU2015204597B2 (en) 2020-04-30
JP2020007355A (ja) 2020-01-16
CN115708827A (zh) 2023-02-24
KR102444494B1 (ko) 2022-09-20
NZ721934A (en) 2022-04-29
US20230104303A1 (en) 2023-04-06
US20200038331A1 (en) 2020-02-06
KR20160104725A (ko) 2016-09-05
KR20220130251A (ko) 2022-09-26

Similar Documents

Publication Publication Date Title
HK1244826A1 (zh) 用於過繼細胞治療的方法和組合物
HK1245829A1 (zh) 受控消除治療性細胞的方法
HK1243333A1 (zh) 用於修飾的t細胞的方法和組合物
HK1244841A1 (zh) 用於選擇性消除所關注細胞的方法和組合物
HK1243640A1 (zh) 用於治療潰瘍的方法和組合物
GB201609438D0 (en) Compositions and methods for cell targeted HPV treatment
IL246352A0 (en) Preparations and methods for preparing airway cells
EP3331582A4 (fr) Procédés et compositions pour le traitement de cellules de transplantation
HK1232152A1 (zh) 用於治療異常細胞生長的方法和組合物
SI3102673T1 (sl) Postopki in sestavki za zdravljenje beta talasemije
HK1244429A1 (zh) 特別用於治療注意力缺陷障礙的方法和組合物
LT3157534T (lt) Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui
EP3201225A4 (fr) Méthodes et compositions pour le traitement d'affections associées à des triglycérides élevés
EP3226972A4 (fr) Méthodes et compositions pour le traitement de la migraine et d'états pathologiques associés à la douleur
IL292054A (en) Preparations for the treatment of abnormal cell growth
RS62981B1 (sr) Kompozicije i postupci za stimulaciju matičnih ćelija
EP3164132A4 (fr) Méthodes et compositions pour le traitement de maladies et d'affections
EP3142674A4 (fr) Methodes et compositions pour le traitement de troubles liés aux macrophages
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
IL248846A0 (en) Methods and preparations of dezotraline for the treatment of adhd
GB201418268D0 (en) Composition & methods of treatment
GB201418272D0 (en) Composition & methods of treatment